Has Amin Rahmatullah, MD received payments from drug or device companies?

Yes. Drug and device makers reported $16,356 in general payments to Amin Rahmatullah, MD across 64 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Amin Rahmatullah, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Amin Rahmatullah, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Amin Rahmatullah, MD

Cardiovascular Disease · Minneapolis, MNNPI 1144268764

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $11,971 of the $16,356 with a category attached, or 73.2%. Canon Medical Informatics, Inc. accounts for 70.9% of it on its own, with 10 other manufacturers making up the rest. 2025 is the largest year on record at $8,591, 3.5 times the $2,485 reported in 2019.

$16,356in general payments, 2019–2025

Across 64 payments — averaging $255.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Canon Medical Informatics, Inc.$12K
Abbott$2K
Heartflow, Inc.$1K
Cvrx, Inc.$843
Edwards Lifesciences$196
Ancora Heart, Inc.$193
plus $336 from 5 others

$11,410in research payments, 2019–2025

Across 1 payment — averaging $11,410 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Novartis$11K

What the payments were for

Speaking & faculty fees$11,97173%
Travel & lodging$2,07813%
Food & beverage$2,30714%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Canon Medical Informatics, Inc.	6	$11,600
Abbott	24	$2,185
Heartflow, Inc.	12	$1,002
Cvrx, Inc.	9	$843
Edwards Lifesciences	3	$196
Ancora Heart, Inc.	3	$193
Boston Scientific	2	$153
Cleerly, Inc.	1	$101
Daxor Corporation	2	$43
Medtronic	1	$25
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)	1	$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$16,356 in reported general payments places this provider in the 75th percentile of 451 cardiovascular disease providers in Minnesota.

See all cardiovascular disease providers in Minnesota →

Medicare billing

Part B allowed, 2024

$57,288

Medicare patients

502

Services billed

952

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
OpsumitMacitentan	73	$947,626
Tyvaso DpiTreprostinil	19	$836,064
UptraviSelexipag	27	$679,505
AdempasRiociguat	12	$165,615
EliquisApixaban	91	$90,984
EntrestoSacubitril/Valsartan	52	$67,795
XareltoRivaroxaban	44	$54,583
JardianceEmpagliflozin	44	$44,359
Sildenafil Citrate	18	$5,209
Metoprolol Succinate	185	$3,573
Bumetanide	50	$2,206
Rosuvastatin Calcium	146	$1,906
Atorvastatin Calcium	76	$1,170
Carvedilol	102	$1,083
Losartan Potassium	88	$1,048

Paid to pharmacies, not to this prescriber.

Other cardiovascular disease in Minneapolis

Jeffrey ChambersMinneapolis$3.2M
Markus MeyerMinneapolis$786K
Robert SchwartzMinneapolis$502K
Robert VantasselMinneapolis$493K
Nedaa SkeikMinneapolis$453K
Joao CavalcanteMinneapolis$384K
Inderjit AnandMinneapolis$384K
David HurrellMinneapolis$205K
Yader Sandoval PichardoMinneapolis$157K
Charles HerzogMinneapolis$157K

See the full list for Minnesota →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →